MOUD Buprenorphine Subli denied as non-formulary by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Sublingual Buprenorphine as Non-Formulary

Sublingual buprenorphine products exist in multiple branded and generic forms, and Aetna's formulary for any given plan may prefer one formulation or manufacturer over others. A non-formulary denial for sublingual buprenorphine typically means your specific product (e.g., a particular branded version) is on a non-preferred tier or is excluded from the plan formulary, while a therapeutically similar alternative is preferred. It does not mean that buprenorphine therapy itself is excluded.

## Why This Denial Is Appealable

Non-formulary denials for MOUD medications are appealable through a formulary exception process when the preferred alternative is medically inappropriate for the patient. Reasons a specific sublingual buprenorphine formulation may be medically necessary over a formulary alternative include documented adverse reactions or tolerability issues with the preferred product, film versus tablet delivery differences that affect absorption or compliance in this patient, or prior stabilization on a specific formulation where switching creates clinical risk. In addition, under MHPAEA, Aetna cannot apply more restrictive formulary access requirements to SUD medications than to comparable medical/surgical treatments.

## Your Federal Appeal Rights

• Formulary exception / internal appeal: Request a formulary exception at the same time as or instead of a standard internal appeal. The exception process is specifically designed for this situation.
• MHPAEA parity: If the non-preferred tier placement or exclusion is more restrictive than formulary management applied to comparable medical conditions, a parity argument applies.
• External review (ACA §2719): After internal exhaustion, an independent external reviewer issues a binding decision. The window is approximately 4 months from the final internal denial.
• Expedited review: Available for urgent clinical situations; 72-hour turnaround.

## Documentation to Gather

1. Formulary alternative list — obtain the list of preferred sublingual buprenorphine products under your specific plan. 2. Prior formulation history — if you have been stable on the prescribed product, document the duration of stability and the clinical risk of switching. 3. Adverse reaction or tolerability record — if you have tried the preferred alternative and it was problematic, document that with dates and the treating clinician's notes. 4. Prescriber formulary exception letter — addressing why the non-formulary product is medically necessary for this patient and why the formulary alternative is inadequate. 5. Treatment continuity argument — if changing formulations mid-treatment poses a risk to recovery, the prescriber should articulate that explicitly.

## Criteria-Mapping Structure

Request Aetna's formulary exception criteria for buprenorphine products from their provider portal. Confirm which alternative is preferred and what criteria apply to an exception. Build your appeal as a one-to-one response to each criterion: preferred alternative, reason it is inadequate for this patient, chart evidence, and prescriber attestation. Treatment stability and documented history of prior formulation response are typically the strongest arguments in this category.